Cardiac Arrhythmias

1. Propafenone, Flecainide and Mexiletine in the Treatment of Stable Ventricular Premature Beats

   • H.-W. Klempt, A. Nayebagha

   Pages 171-178

2. Long-term Prognosis for Patients with Complex Ventricular Arrhythmias of Lown Grades IV a and IV b

   • F. Theisen, K. Theisen, H. Jahrmärker

   Pages 179-184

3. Experience with Propafenone in the Treatment of Arrhythmias in Pediatric Patients

   • H. Weber, G. Eigster, H. Wesselhoeft

   Pages 185-190

4. Electrophysiologic Effects and Antiarrhythmic Efficacy of Rytmonorm Evaluated with Programmed Electrical Stimulation of the Heart in Patients with Recurrent Reentrant Supraventricular Tachycardia

   • A. Waleffe, H. Kulbertus

   Pages 191-198

5. Antiarrhythmic Effect and Study of Segmentary Contractility Following the Administration of Propafenone in Coronary Patients with Ventricular Arrhythmias

   • J. L. Palma, A. Bayés de Luna, M. Fiol, P. Yuste, V. Aza, J. Sadurni et al.

   Pages 199-210

6. Propafenone in Office Use: Results of an Open, Multicenter Study

   • H.-F. Spies, F. Sesto

   Pages 211-215

7. The Safety and Efficacy of Propafenone in Suppressing Ventricular Ectopy

   • N. deSoyza, M. Murphy, M. Sakhaii, L. Treat

   Pages 217-219

8. Dose-Response Effect of Propafenone in Patients with Ventricular Arrhythmias

   • P. Larochelle, L. Belanger, F. Lemire, D. Phaneuf, R. Huot

   Pages 221-230

9. Treatment of Severe Ventricular Arrhythmias with Propafenone

   • L. Ledain, N. Sourdille, J. P. Colle, J. Ohayon, P. Besse

   Pages 231-236

10. Use of Propafenone for the Prevention of Ventricular Hyperkinetic Arrhythmias in the Mitral Valve Prolapse Syndrome

    • F. Furlanello, G. B. Durante, P. Dal Forno, L. Frisanco, G. Mosna, R. Bettini et al.

    Pages 237-238

Asked to organize an international meeting on Propafenone (Ryt­ monorm) we had to question ourselves, whether to accept this offer just as interested physicians or in our capacity as chairmen of the study group on arrhythmias and intracardiac electrography of the European Society of Cardiology. Considerung the "pros and contras" and well aware that one can easily be regarded as "product promoter" we, nevertheless, choose to organize the Symposion in association with the study group. We felt justified to do so for a number of reasons: Arrhyth­ mias and their treatment as well as the tools to detect the first and to control the latter are well within the scope of the study group. An international symposion provided the opportunity to have the "state of the art" in arrhythmias and antiarrhythmic treatment thoroughly reviewed by internationally renowned investigators, thus serving an educational purpose. Furthermore it was the intention and aim of the meeting to have what is known about a fairly new drug presented in a critical manner and to point out what is not known, but should be known. It is in that context the presentations of the free session should be judged. To the careful reader it will become apparent that much which was not said, can be read "between the lines".

• arrhythmia
• cardiology
• diagnosis
• drug
• drugs
• education
• electrocardiography
• heart
• hemodynamics
• myocardial infarction
• sudden cardiac death
• therapy
• treatment

• Kerckhoff-Klinik of the Max-Planck-Society, Bad Nauheim, Germany

  M. Schlepper

• Department of Cardiology, Sahlgrenska University Hospital, Göteborg, Sweden

  B. Olsson

Policies and ethics